Delving into the Latest Updates on Recombinant anti-CD20 humanized monoclonal antibody(Shanghai Pharmaceuticals Holding Co., Ltd.) with Synapse

Overview

Basic Info

Drug Type

Monoclonal antibody

Synonyms

重组抗CD20人源化单克隆抗体（上海医药集团）

+ [1]

Target

CD20

Action

inhibitors

Mechanism

CD20 inhibitors(B-lymphocyte antigen CD20 inhibitors), ADCC(Antibody-dependent cell-mediated cytotoxicity (ADCC) effects), CD20-directed cytolytic effects

+ [1]

Therapeutic Areas

NeoplasmsImmune System DiseasesInfectious Diseases+ [3]

Active Indication

AQP4-IgG positive Neuromyelitis optica spectrum disorderAQP4-IgG positive Optic Neuritis

Inactive Indication

CD20 Positive B-Cell Non-Hodgkin Lymphoma

Originator Organization

Shanghai Pharmaceuticals Holding Co., Ltd.

Active Organization

Shanghai Pharmaceuticals Holding Co., Ltd.

Inactive Organization

Yongzhuo Boji (Shanghai) Biomedical Technology Co., Ltd.

License Organization-

Drug Highest PhasePhase 2/3

First Approval Date-

Regulation-

Login to view timeline

Numerous studies have shown that hand, foot and mouth disease (HFMD) pathogen Coxsackievirus A16 (CVA16) can also cause severe neurological complications and even death. Currently, there is no effective drugs and vaccines for CVA16. Therefore, developing a drug against CVA16 has become critical. In this study, we conducted two strategies-virtual screening (VS) and fragment replacement to obtain better candidates than the known drug GPP3. Through VS, 37 candidate drugs were screened (exhibiting a lower binding energy than GPP3). After toxicity evaluations, we obtained five candidates, analysed their binding modes and found that four candidates could enter the binding pocket of the GPP3. In another strategy, we analysed the four positions in GPP3 structures by the FragRep webserver and obtained a large number of candidates after replacing different functional groups, we obtained eight candidates (that target the four positions above) with the combined binding score and synthetic accessibility evaluations. AMDock software was uniformly utilized to perform molecular docking evaluation of the candidates with binding activity superior to that of GPP3. Finally, the selected top three molecules (Lapatinib, B001 and C001) and its interaction with CAV16 were validated by molecular dynamics (MD) simulation. The results indicated that all three molecules retain inside the pocket of CAV16 receptor throughout the simulation process, and he binding energy calculated from the MD simulation trajectories also support the strong affinity of the top three molecules towards the CVA16. These results will provide new ideas and technical guidance for designing and applying CVA16 therapeutics.Communicated by Ramaswamy H. Sarma.

01 Sep 2019·Analytical and Bioanalytical Chemistry

Two-component ratiometric sensor for Cu2+ detection on paper-based device

Article

Author: Zhang, Gaobin ; Lu, Yao ; Huang, Wei ; Wu, Meirong ; Chen, Xingwei ; Li, Lin ; Wu, Qiong ; Zhou, Jia ; Fang, Haixiao ; Yu, Haidong ; Qin, Xiaofei

The copper(II) ion (Cu²⁺) has played an indispensable role in diverse kinds of functional physiological processes of organisms, which has become of growing interest. Despite the fact that numerous Cu²⁺ test papers using fluorescent probes have been fabricated, sensors featuring the ratiometric property that integrates quenched probes and an inner standard dye are rarely reported. Herein, a two-component ratiometric sensor in a paper-based device is proposed to realize highly selective Cu²⁺ detection. To overcome shortcomings such as low signal-to-noise ratio and incorrect response of the quenching probe, a novel BODIPY-based turn-off probe (P2017) is designed and introduced into the paper-based device with better water solubility and selectivity for Cu²⁺ detection. Furthermore, a reference dye (B001), exhibiting an emission at 690 nm when the excitation wavelength is 480 nm, is also introduced into the paper-based device. These two components can enhance the quality of the signal as P2017 is sensitively quenched by Cu²⁺, while B001 with a photostable property, serving as an internal benchmark, is unable to react with Cu²⁺. The results indicated that the two components provided a new concept for optimizing paper-based device fabrication and developing accurate, simple, and inexpensive Cu²⁺ detection methods, which could be potentially applied to monitor human health and the environment in remote areas. Graphical abstract.

01 Jun 2017·Pest Management ScienceQ1 · AGRICULTURAL & FORESTRY SCIENCE

Combined use of Bacillus subtilis strain B‐001 and bactericide for the control of tomato bacterial wilt

Q1 · AGRICULTURAL & FORESTRY SCIENCE

Article

Author: Jiang, Huidan ; Peng, Di ; Bai, Lianyang ; Zhou, Xiaomao ; Deng, Yanan ; Luo, Kun

AbstractBACKGROUNDTomato bacterial wilt caused by Ralstonia solanacearum poses a serious threat to tomato production. However, no effective control measures are available. In this study, the bactericide Saisentong was combined with an effective biological control agent, Bacillus subtilis B‐001, to control tomato bacterial wilt under greenhouse and field conditions.RESULTSGrowth of B‐001 in vitro was unaffected by Saisentong. In greenhouse experiments, the combined application of B‐001 and Saisentong via root irrigation or spray resulted in better disease control compared with either agent alone. In two field trials, at a Saisentong concentration of 400 or 500 mg kg−1, the combined treatment was more effective than expected and showed a synergistic effect. A lower concentration of Saisentong (200 or 300 mg kg−1) in combination with B‐001 resulted in an antagonistic effect. However, disease control was significantly greater compared with either treatment alone.CONCLUSIONThe combination of Saisentong and B‐001 effectively controls tomato bacterial wilt. The integrated strategy represents a promising new tool to control this disease. © 2016 Society of Chemical Industry

100 Deals associated with Recombinant anti-CD20 humanized monoclonal antibody(Shanghai Pharmaceuticals Holding Co., Ltd.)

Login to view more data

R&D Status

10 top R&D records.

Login

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
AQP4-IgG positive Neuromyelitis optica spectrum disorder	Phase 3	China	Shanghai Pharmaceuticals Holding Co., Ltd.	02 Jul 2024
AQP4-IgG positive Optic Neuritis	Phase 1	China	Shanghai Pharmaceuticals Holding Co., Ltd.	07 Apr 2022
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Preclinical	China	Shanghai Pharmaceuticals Holding Co., Ltd.	22 Mar 2018
CD20 Positive B-Cell Non-Hodgkin Lymphoma	Discovery	China	Shanghai Pharmaceuticals Holding Co., Ltd.	22 Mar 2018

Login to view more data

Clinical Result

Indication

Phase

Evaluation

View All Results

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.

login

or

view full example data

Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.

login

or

view full example data

Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.

login

or

view full example data

Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.

login

or

view full example data

Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.

login

or

view full example data

Accelerate your research with the latest regulatory approval information.

Biosimilar

Competitive landscape of biosimilars in different countries/locations. Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3.

login

or

view full example data